Volunteers aged 18-60 with non-complicated influenza (not exceeding 2 days) are recruited for the placebo-controlled, blind, prospective Phase 2 trial of the antiviral drug Triazavirin.
The purpose of this study is to show efficacy and safety of the novel antiviral drug, developed jointly by RII and the Ural Institute of Organic Synthesis. Its field of use is against influenza, including A(H5N1) and pandemic A(H1N1)2009 strains. Phase 1 of the clinical trial was successfully completed and showed a good safety and tolerability record of Triazavirin.
Clinical studies of Triazavirin were authorized by the Federal Service on Surveillance and Healthcare in Social Development (Roszdravnadzor).
/
News
